Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT02749019
Dual Integrin αvβ3 and GRPR Targeting PET Imaging in Breast Cancer Patients
Overview
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-BBN-RGD in breast cancer patients. A single dose of 111-148 Mega-Becquerel (MBq) 68Ga-NOTA-BBN-RGD will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.
Phase
Phase 1
Contacts
Jingjing Zhang, MD. PhD (CONTACT)
zhangjingjing@pumch.cn
+86 10 69155513
Zhaohui Zhu, MD. PhD. (CONTACT)
zhuzhh@pumch.cn
+86 10 69154196
ClinicalTrials.gov
NCT02749019Drug / Compound
BBN-RGD
Isotope(s):
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- GRPR
Ligand Class: Peptides
Chelator: NOTA
Linker: glutamate
Eligibility
Inclusion
- Neoplasm identified by X-ray, ultrasound or MRI as breast cancer
Exclusion
- Severe allergy or hypersensitivity to IV radiographic contrast
- Severe liver or kidney disease with serum creatinine \> 3.0 mg/dl (270 μΜ) or any hepatic enzyme level 5 times or more than normal upper limit;
- Claustrophobia to accept the PET/CT scanning
- Consisted of conditions of mental illness;
- Pregnancy or breast feeding
Share your feedback
Help us improve your experience